Average Co-Inventor Count = 16.84
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Array Biopharma Inc. (10 from 329 patents)
2. Petra Pharma Corporation (3 from 4 patents)
3. Eli Lilly and Company (1 from 4,442 patents)
14 patents:
1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
2. 11878970 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
3. 11873295 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
4. 11649227 - Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease
5. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
6. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
7. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
8. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
9. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
10. 10172845 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
11. 10172851 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
12. 10144734 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
13. 10137124 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
14. 10112942 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors